Frantz v. Secretary of Health and Human Services

In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

**********************

SIERRA FRANTZ, *

* No. 13-158V

Petitioner, * Special Master Christian J. Moran

*

v. * Filed: June 24, 2019

*

SECRETARY OF HEALTH * Attorneys’ Fees and Costs, reasonable

AND HUMAN SERVICES, * basis

*

Respondent. *

**********************

Ronald C. Homer & Christina Ciampolillo, Conway, Homer, P.C., Boston, MA,

for Petitioner;

Daniel Principato & Debra A. Filteau Begley, United States Dep’t of Justice,

Washington, DC, for Respondent.

PUBLISHED DECISION AWARDING ATTORNEYS’ FEES AND COSTS1

Sierra Frantz claimed that vaccines caused her to develop a demyelinating

condition, later diagnosed as multiple sclerosis, a condition marked by lesions in

the central nervous system. She retained two experts to assist her, and the

Secretary matched with two experts. In a ruling from the bench, the undersigned

found that the evidence showed that Ms. Frantz was already suffering from pre-

clinical multiple sclerosis when she received the allegedly causal vaccines. The

primary evidence supporting this finding was an article Francois Cotton wrote in

2003 about the duration of lesion enhancement. Because Ms. Frantz had at least

one lesion in her brain that probably existed before the vaccinations, the vaccines

1

The E-Government Act, 44 U.S.C. § 3501 note (2012) (Federal Management and

Promotion of Electronic Government Services), requires that the Court post this decision on its

website. This means the decision will be available to anyone with access to the internet.

Pursuant to Vaccine Rule 18(b), the parties have 14 days to file a motion proposing redaction of

medical information or other information described in 42 U.S.C. § 300aa-12(d)(4).

could not have caused the demyelinating condition. Thus, Ms. Frantz was not

awarded compensation.

Following this denial of compensation, Ms. Frantz moved for final

attorneys’ fees and costs. She requested $326,914.44, later amended to

$352,451.91. The Secretary countered that because Ms. Frantz had not established

a reasonable basis for the claim set forth in her petition, Ms. Frantz should receive

no attorneys’ fees and costs. The parties subsequently developed their positions on

reasonable basis and then participated in an oral argument on that issue. For the

reasons explained below, she is awarded $135,187.59.

* * *

I. Background

A. Cotton and W.C.

The Cotton article was a key aspect of the decision denying Ms. Frantz

compensation.2 Cotton was discussed in a case highly similar to Ms. Frantz’s case,

W.C. v. Sec’y of Health & Human Servs., No. 07-456V, 2011 WL 4537877 (Fed.

Cl. Spec. Mstr. Feb. 22, 2011), mot. for rev. denied on relevant grounds, 100 Fed.

Cl. 440 (2011), aff'd, 704 F.3d 1352 (Fed. Cir. 2013). Thus, this background

material is set forth to provide context for the developments in Ms. Frantz’s case.

Like Ms. Frantz, W.C. was a healthy individual who received a flu

vaccination, developed neurologic symptoms, and was diagnosed with multiple

sclerosis. W.C., 2011 WL 4537877, at *2-3. Represented by the same law firm

that represents Ms. Frantz, W.C. alleged that the flu vaccination caused him to

develop multiple sclerosis. W.C. retained Carlo Tornatore, a neurologist, who

offered an opinion that the vaccine did, in fact, cause W.C. to develop multiple

sclerosis. The Secretary presented the view of Arun Venkatesan, also a

neurologist. Dr. Venkatesan opined that the presence of non-enhancing lesions on

W.C.’s initial MRI meant that the lesions must have formed before the vaccination.

The parties were instructed to present evidence about how long lesions enhance on

MRIs.

The undersigned found that the Cotton article was the most informative

study. In Cotton, the researchers performed MRI scans on a collection of patients

2

Exhibit D, Tab 3 - Francois Cotton et al., MRI Contrast Uptake in New Lesions in

Relapsing-remitting MS Followed at Weekly Intervals, 60 Neurology 640 (2003).

2

every week. This level of regularity made the Cotton research more granular than

earlier studies in which the MRIs were repeated monthly. Cotton and colleagues

found that half of the lesions studied were enhancing after 14 days.

The metric from Cotton was then used to evaluate the MRI that W.C.

underwent 17 days after vaccination. W.C.’s initial MRI showed six non-

enhancing lesions and no enhancing lesions. The presence of non-enhancing

lesions, combined with the knowledge about the duration of enhancement Cotton

supplied, was the basis for Dr. Venkatesan’s opinion that W.C.’s lesions pre-dated

the vaccination.

The (undersigned) special master credited Dr. Venkatesan’s opinion and

found Dr. Tornatore’s contrary opinion unpersuasive. The undersigned found that

W.C.’s first MRI was taken close enough in time to the vaccination that at least

one lesion of the six lesions should have been in the enhancing phase. However,

W.C.’s lesions were not enhancing, which implies that the lesions were beyond the

initial enhancing phase and could not have been caused by the vaccination. Thus,

the (undersigned’s) decision found that W.C.’s lesions pre-existed the vaccination

and the vaccination could not have caused the lesions.

Still represented by the same attorneys, W.C. filed a motion for review.

The Court of Federal Claims evaluated whether the factual finding regarding the

duration of lesion enhancement was arbitrary or capricious. W.C., 100 Fed. Cl.

440, 451 (2011), aff'd, 704 F.3d 1352 (Fed. Cir. 2013). The Court described the

special master’s interpretation of the range of enhancement for lesions in the

Cotton article and did not dispute that interpretation. Id. at 451-53. The Court

agreed that the lesion enhancement timeline proposed by W.C. was possible but

also stated that the special master’s finding of a longer enhancement timeline was

“quite possible.” Id. at 453. The Court found that the special master’s finding on

the duration of lesion enhancement was not arbitrary or capricious. Id. at 461. The

Court, consequently, denied the motion for review.

W.C. next appealed to the Federal Circuit. The Federal Circuit again

evaluated the special master’s finding on the duration of lesion enhancement under

the arbitrary or capricious standard. W.C., 704 F.3d 1352, 1355 (Fed. Cir. 2013).

The Federal Circuit agreed with the special master’s explanation of the

enhancement timeline for lesions described in Cotton. Id. at 1359. Further, the

Federal Circuit found that the special master’s finding on the duration of lesion

enhancement was not arbitrary or capricious and that the special master’s finding

that W.C.’s lesions pre-existed the vaccination was also neither arbitrary nor

capricious. Id. at 1359-60. Thus, the Federal Circuit affirmed the judgment

3

denying compensation. Id. at 1361. The Federal Circuit issued its opinion on

January 13, 2013, a few months before Ms. Frantz filed her petition.

B. Brief Factual Summary for Ms. Frantz

At twelve years old, Ms. Frantz had previously received all her scheduled

vaccinations and was generally healthy. On August 6, 2010, Ms. Frantz received

the tetanus-diphtheria-acellular pertussis (“Tdap”) and hepatitis A vaccinations.

On August 9, 2010, Ms. Frantz’s mother called her doctor and reported that Ms.

Frantz had been off-balance, dizzy and sluggish since August 7, 2010, and later

went with Ms. Frantz to the emergency room for these neurologic symptoms.

Ms. Frantz’s neurologic symptoms worsened, and she underwent her first

MRI on August 12, 2010. This first MRI revealed one enhancing lesion on her

brain stem as well as two non-enhancing lesions in her upper medulla and left

periventricular region. After subsequent MRIs, Ms. Frantz was ultimately

diagnosed with multiple sclerosis. Ms. Frantz continues to receive treatment for

relapsing remitting multiple sclerosis.

C. Entitlement Litigation

Ms. Frantz sought compensation under the Nation Vaccine Injury

Compensation Program, 42 U.S.C. § 300aa-10 through 34, alleging that the Tdap

and hepatitis A vaccinations she received on August 6, 2010, caused her to develop

a “neurological demyelinating injury.” Pet., filed Mar. 4, 2013, at 1. After

completing her initial submission of medical records, Ms. Frantz filed a statement

of completion on January 13, 2014.

The Secretary reviewed Ms. Frantz’s evidence and recommended against an

award of compensation. Resp’t’s Rep., filed May 1, 2014. In the Secretary’s

recitation of Ms. Frantz’s medical history, he noted that the August 12, 2010 MRI

detected two non-enhancing lesions. The Secretary also noted that Ms. Frantz’s

differential diagnosis included acute disseminated encephalomyelitis (“ADEM”)

and multiple sclerosis. The Secretary argued that compensation was not

appropriate because Ms. Frantz had not offered a medical theory connecting the

vaccinations to her symptoms and that the temporal association between the

vaccinations and the onset of symptoms was insufficient to establish causation. Id.

at 8-10.

During a May 12, 2014 status conference to discuss the Rule 4 report, the

Secretary again raised the issue that a one-day onset of symptoms was a problem

with the feasibility of Ms. Frantz’s claim. In the subsequently issued expert

4

instructions, the experts were directed to identify all pertinent medical facts that

support their position. Expert Instructions., issued June 16, 2014, at 3.3

Ms. Frantz filed the first report from Dr. Tornatore on November 25, 2014.

In the medical history and summary, Dr. Tornatore noted an enhancing lesion and

two non-enhancing lesions in the August 12, 2010 MRI. Exhibit 36 at 5, 56. Dr.

Tornatore opined that Ms. Frantz first suffered from ADEM that subsequently

evolved into multiple sclerosis. Id. at 57. Dr. Tornatore further opined that

ADEM could have an onset as early as two days post-vaccination, but vaguely

stated that Ms. Frantz’s symptoms started “several days” post-vaccination. Id. at

58.

Following a status conference discussing Dr. Tornatore’s first report, the

undersigned ordered a supplemental report from Dr. Tornatore to address the

Althen prongs more fully and to answer other specific questions. Order, issued

Dec. 3, 2014. Ms. Frantz filed a supplemental report from Dr. Tornatore. He

stated that the first neurologic symptoms of Ms. Frantz’s disease occurred on

August 7, 2010, the day after the vaccination. Exhibit 38 at 6. Comparing the wild

pertussis infection that precedes the onset of ADEM with the pertussis toxin in the

Tdap vaccine, Dr. Tornatore argued that the Tdap vaccine could cause ADEM. Id.

at 4.

On April 30, 2015, respondent filed the first report from Subramaniam

Sriram, also a neurologist. Dr. Sriram responded to Dr. Tornatore’s report but

noted that he had not reviewed the MRIs, only the descriptions of the MRIs in the

medical records. Exhibit A at 1. In regard to timing, Dr. Sriram noted that the

lesion on Ms. Frantz’s medulla would have caused her ataxia (failure of muscular

coordination) two days after the vaccinations but opined that it was “highly

unlikely” for the medullary lesion to have appeared in two days. Id. at 7. Dr.

Sriram further doubted that the medullary lesion could have even developed within

six days, the time span between vaccinations and the August 12, 2010 MRI, and,

thus, did not believe the vaccinations caused this lesion. Id.

A status conference was held on May 11, 2015, to discuss the expert reports.

Dr. Sriram was ordered to file a supplemental statement to address some omitted

3

Although Ms. Frantz challenged the instructions on the basis that the expert reports

should not constitute direct testimony, special masters possess the authority to structure the

submission of evidence. Order, issued June 16, 2014; see also K.L. v. Sec’y of Health & Human

Servs., 134 Fed. Cl. 579, 601-05 (2017).

5

qualifications questions,4 and Dr. Tornatore was ordered to file a supplemental

report to address some inconsistencies in his opinions regarding timing. Order,

issued May 13, 2015. The timing inconsistency was that Dr. Tornatore had at one

point proposed that an appropriate interval for vaccines to cause ADEM was 2-30

days but at another point had stated that Ms. Frantz’s symptoms began the day

after the vaccination. Id. During the conference, the Secretary noted that he was

considering whether to file a motion for summary judgment.

Following the May 11, 2015 status conference, paralegals at the law firm

representing Ms. Frantz requested and eventually obtained MRI films. E.g., time

entry for 5/22/2015. In addition, the attorney for Ms. Frantz sent literature to Dr.

Tornatore. Time entries for 6/2/2015 and 6/9/2015. Dr. Tornatore presented a

third report on August 7, 2015. Exhibit 39. Dr. Tornatore argued that the Tdap

vaccination at issue constituted a rechallenge to Ms. Frantz’s immune system and

in that circumstance the “immune response would be expected to be brisk,” noting

that a vaccine injury can generally occur in 1-3 days. Id. at 3. For the range of 1-3

days, Dr. Tornatore relied upon the IOM’s report of a lag phase. Id. (citing exhibit

39, tab D, at 58).

At the August 27, 2015 status conference, the parties discussed Dr.

Tornatore’s recent report and respondent noted that she had forwarded the MRIs to

Dr. Sriram for review to draft another report. Order, issued Aug. 28, 2015.

On December 4, 2015, the Secretary filed another report from Dr. Sriram

primarily discussing diagnosis. In the discussion, Dr. Sriram stated that Ms.

Frantz’s two non-enhancing lesions predated the vaccinations because of the short

time between vaccination and the MRI such that the lesions could not enhance and

become non-enhancing in that short of a time period. Exhibit D at 1, 4 (citing

exhibit D tab 3 (Cotton). Dr. Sriram believed that that Ms. Frantz had at least

subclinical neurological events pre-vaccination. Exhibit D at 4.

On December 15, 2015, a status conference was held to discuss Dr. Sriram’s

recent report. Based on Dr. Sriram’s conclusion that the two non-enhanced lesions

predated the vaccinations, the undersigned stated that Ms. Frantz “probably cannot

prevail on a claim that vaccination caused her neurologic condition,” and cited

W.C. v. Sec’y of Health & Human Servs., 704 F.3d 1352 (Fed. Cir. 2013), for that

proposition. Order, issued Dec. 15, 2015. In response to the order, Dr. Sriram

4

On May 27, 2015, Dr. Sriram filed a statement addressing the omitted qualifications

questions. Exhibit C.

6

filed a brief report to confirm that MRIs are only in black and white and to address

another question regarding the blood brain barrier. Exhibit E.

After the December 15, 2015 status conference, two attorneys representing

Ms. Frantz often conferred about “med lit.” See timesheets at internal pages 65-

67. However, the attorneys’ entries do not identify what articles they were

reviewing. None of the entries from this time specifically list Cotton as an article

being reviewed.

On March 16, 2016, Ms. Frantz filed a fourth report from Dr. Tornatore. Dr.

Tornatore did not challenge the usefulness of the Cotton article in measuring the

duration of lesion enhancement. Rather, Dr. Tornatore contested the reliability of

Ms. Frantz’s August 12, 2010 MRI. Dr. Tornatore speculated that if the MRI used

a different enhancement technique, then the two lesions may have been revealed to

be enhancing and, therefore, be newer and have developed after the vaccinations.

Exhibit 40 at 3-4.

After an April 22, 2016 status conference, the parties were directed to

coordinate on hearing dates in early 2017, and respondent arranged to submit a

report from another expert to address whether the design and manufacturing

process for the Tdap vaccine affects the comparability of the wild pertussis

bacteria and the modified pertussis toxin contained in the vaccine. Order, issued

Apr. 22, 2016. A pre-hearing briefing schedule was subsequently set. Order,

issued May 10, 2016.

On June 21, 2016, the Secretary filed the first report from Thomas

Forsthuber, an immunologist. Dr. Forsthuber disputed, among other issues, Dr.

Tornatore’s timing for Ms. Frantz’s onset of neurologic symptoms. Exhibit F at 8-

9. Dr. Forsthuber concluded that Ms. Frantz’s onset of neurologic symptoms was

too early to have been caused by her vaccinations. Id. at 9. As for vaccine design,

Dr. Forsthuber argued that Dr. Tornatore’s comparison of wild type pertussis and

the pertussis toxin in the Tdap vaccine was inapt because the Tdap vaccine is

chemically detoxified. Id. at 7. Due to the chemical detoxification, the Tdap

vaccine would contain an inactive pertussis toxin that would not create a similar

immune reaction to wild pertussis. Id.

Ms. Frantz filed a motion in limine to exclude Dr. Forsthuber’s opinions

outside the anticipated issue of vaccine design. The Secretary filed a response to

the motion, and then Ms. Frantz filed a reply. The undersigned denied the motion

in limine on the basis that Ms. Frantz had adequate time to address Dr.

Forsthuber’s arguments beyond vaccine design with another report from Dr.

7

Tornatore or another expert. Order, issued Sept. 9, 2016. In the event that Ms.

Frantz wanted to retain another expert, the undersigned stated a willingness to

reschedule the entitlement hearing. Id.

At a September 26, 2016 status hearing, Ms. Frantz advised that she had

retained another expert, Lawrence Steinman, a neurologist with experience in

designing vaccines. The parties also discussed the possibility of delaying the

entitlement hearing. Order, issued Sept. 27, 2016.

Ms. Frantz filed another report from Dr. Tornatore disputing some details of

Dr. Forsthuber’s report. Exhibit 42. After a status conference on November 4,

2016, the entitlement hearing was set for September 27-29, 2017. Order, issued

Nov. 16, 2016. Ms. Frantz agreed to those dates despite knowing that due to

previous commitments in the schedules of Dr. Tornatore and Dr. Steinman, her

experts would not attend the entire three-day hearing. Id.

Ms. Frantz filed the first report from Dr. Steinman on January 17, 2017. Dr.

Steinman incorporated Dr. Tornatore’s medical history and summary from his first

report, including the notation of the August 12, 2010 MRI showing one enhancing

lesion and two non-enhancing lesions, as a basis to support timing. Exhibit 43 at

5-6, 40-41. Dr. Steinman did not directly state the expected onset of neurological

symptoms following the vaccinations but noted that “vigorous recall immunity” of

the vaccinations could fit Ms. Frantz’s time frame. Id. at 12, 41.

The Secretary filed a response to Dr. Steinman’s report from Dr. Forsthuber

on March 27, 2017. Dr. Forsthuber noted that Dr. Steinman had adopted the

August 9, 2010 onset of symptoms from Dr. Tornatore’s first report but did not

acknowledge that Dr. Tornatore later stated Ms. Frantz’s onset of neurologic

symptoms as August 7, 2010. Exhibit G at 13 (citing exhibit 43 at 40, exhibit 38 at

4). Dr. Forsthuber disputed Dr. Steinman’s asserted homology between the

hepatitis A vaccine and other vaccines and, thus, concluded that Ms. Frantz would

not have experienced a recall response, and a faster onset of symptoms, to the

hepatitis A vaccination. Id.

On April 11, 2017, the undersigned issued an order outlining the content of

pre-hearing briefs and establishing a briefing schedule. The order noted the

parties’ differences on the expected onset of Ms. Frantz’s symptoms and the actual

onset. Order, issued Apr. 11, 2017, at 7-8. At a May 1, 2017 status conference to

discuss the briefing instructions, the undersigned advised the parties that based on

his review of the evidence, Ms. Frantz may lack a reasonable basis to bring the

case to an entitlement hearing. Order, issued May 4, 2017. In support of this

8

assessment, the undersigned pointed out Ms. Frantz’s similarity to W.C. in that in

both cases, the lesions seemed to exist before the vaccination. The undersigned

also noted that the one-day onset that Ms. Frantz’s experts was advancing was also

problematic. Id.

On May 31, 2017, Ms. Frantz filed a final supplemental report from Dr.

Steinman addressing Dr. Forsthuber’s critiques of his report. Exhibit 56.

Ms. Frantz filed her pre-hearing brief on July 27, 2017. In regard to timing,

acknowledging the August 7, 2010 (one-day) onset of symptoms, Ms. Frantz

proposed an “amnestic response” to the vaccinations with rechallenge and recall as

mechanisms to explain the quick onset. Pet’r’s Br. at 53. As for the suggestion

that two of Ms. Frantz’s lesions pre-dated the vaccinations, Ms. Frantz first

questioned why Dr. Sriram had not raised this issue in his first report, only raising

the issue in his second report, and dropped a footnote detailing factual errors in Dr.

Sriram’s reports. Id. at 55 n.35. In another footnote, Ms. Frantz briefly argued that

the Secretary and the undersigned had misinterpreted the Cotton article and the

relevance of W.C. to her case:

In W.C., the Special Master relied upon the Cotton article to conclude

that one would expect to see enhancing lesions on brain MRI seventeen (17)

days after vaccination. 2011 WL 453877 at *7-8. In Sierra’s case, due to

frequent imaging, non-enhancing lesions were documented on a September

14, 2010 [MRI] that did not appear on brain MRI just eighteen (18) days

prior, on August 27, 2010. See Pet. Ex. 9, pp. 1455-1456, 1449-1450; see

also Pet. Ex. 40, p. 2. The MRI findings in Sierra’s case illustrate[] the

arbitrariness of the findings in W.C.

Id. at 54 n.34.

The Secretary filed a supplemental report from Dr. Sriram and his brief on

August 23, 2017. While Dr. Sriram’s report focused on the ADEM diagnosis, he

did cite to the Cotton article as support for the timing of enhancing lesions.

Exhibit H. Dr. Sriram expanded his discussion of the lesions from Ms. Frantz’s

MRI. He now opined that the T1 lesion(s) were hypointense, which are

colloquially known as “black holes.” Black holes develop through a process that

takes several weeks. Thus, Dr. Sriram, again, opined that the lesions from Ms.

Frantz’s August 12, 2010 MRI must have existed before she received vaccinations

on August 6, 2010.

9

In the Secretary’s brief, he argued against an award of compensation on

multiple grounds. For purposes of evaluating the pending question about the

reasonable basis for Ms. Frantz’s claim, the most important arguments concern

timing. For Ms. Frantz’s potentially pre-existing lesions, the Secretary compared

Dr. Sriram’s analysis of Ms. Frantz’s non-enhancing lesions with the lesions in

W.C. with the common thread of the Cotton article. Resp’t’s Br. at 28-32. Overall

for timing, the Secretary argued that even the most extreme immune reactions that

cause central nervous system disease take at least two days. But, because Ms.

Frantz manifested neurologic symptoms only one day after the vaccination, the

vaccination could not have initiated the process leading to her neurologic

symptoms. Id. at 33-34.

During the pre-hearing status conference, the undersigned expressed concern

for whether Ms. Frantz had a reasonable basis to proceed to the hearing. Order,

issued Sept. 14, 2017, at 3. The undersigned declined to determine reasonable

basis at that time but noted that the fact that a hearing was being held did not

indicate that reasonable basis existed. Id.

The entitlement hearing was held in Washington, DC, from September 27-

29, 2017. Although the undersigned had earlier determined that the reports from

the experts would constitute their direct testimony, the undersigned allowed the

parties to conduct short direct examinations to highlight the important points from

the expert’s reports. Order, issued Sept. 14, 2017, at 2.

Ms. Frantz’s attorney presented testimony from Dr. Tornatore at the

beginning of the hearing. During this time, Ms. Frantz elicited no testimony from

Dr. Tornatore about the Cotton article or the expected duration of enhancement for

lesions. See Tr. 14-59. In response to a question not asked by Ms. Frantz, Dr.

Tornatore acknowledged that the Cotton article supported the proposition that the

average duration of lesion enhancement is two weeks. Tr. 186.

Due to scheduling issues, Dr. Sriram testified after Dr. Tornatore. Like Ms.

Frantz, the Secretary was permitted to present direct testimony orally. Order,

issued Sept. 14, 2017, at 2. On direct examination, based on Cotton, Dr. Sriram

noted that the mean duration of enhancement of lesions was three weeks with a

median duration of two weeks. Tr. 279. Because all lesions have an enhancing

phase and Cotton provides a timeframe for how long the enhancing phase could be,

Dr. Sriram argued that Ms. Frantz’s lesions were at least a certain age since they

were no longer enhancing. Tr. 282. On Ms. Frantz’s cross-examination of Dr.

Sriram, she asked about how quickly a black hole could develop but did not seek

clarification of Dr. Sriram’s answer:

10

Q [Ms. Frantz’s counsel]. So would [the time period from the vaccination to

the August 12, 2010 MRI] be six days?

A [Dr. Sriram]. Right.

Q. Okay. So is that within that 1- to 13-day time frame [of the Cotton

article]?

A. Yeah, but she already had hypointensity there. There was T1 hypointense

already there at that time.

Q. Okay.

A. It persisted. So the T1 hypointensities will change. The fact that it was T1

hypointense doesn't make it a five-day event –

Q. Okay.

A. -- or a six-day event.

Q. All right. Dr. Sriram, [changing subjects].

Tr. 367-68.

Dr. Steinman also noted the waxing and waning of lesions in 1 to 13 days

based on the Cotton article. Tr. 422-23. Thus, Ms. Frantz did not present any

meaningful evidence that challenged the findings of Cotton.

During Dr. Sriram’s testimony, the Secretary referred to Ms. Frantz’s MRIs

as visual exhibits. At the conclusion of the hearing, the undersigned issued a

bench ruling denying compensation. Tr. 563-78. The undersigned found that Ms.

Frantz had an onset of symptoms less than two days after receiving the

vaccinations. Tr. 566. Relying on the Cotton article for the duration of lesion

enhancement, the undersigned found that Ms. Frantz’s two non-enhancing lesions

in the August 12, 2010 MRI pre-dated the vaccinations and, thus, the vaccinations

could not have caused Ms. Frantz’s injuries. This conclusion rested on the

continuing persuasiveness of the Cotton article, which Ms. Frantz had not refuted,

and the persuasiveness of Dr. Sriram’s application of the Cotton article to the facts

of this case. Tr. 574-77. On October 3, 2017, the undersigned issued a written

memorialization of the bench ruling. Ms. Frantz did not move for review of the

decision, and judgment was entered on November 6, 2017.

11

D. Fees Litigation

On April 27, 2018, Ms. Frantz filed a motion for final attorneys’ fees and

costs. (“Fees Appl.”). The motion seeks a total of $326,914.44 comprised of

$199,304.90 in attorneys’ fees and $127,609.54 in attorneys’ costs. Fees Appl. at

1-2. Although Ms. Frantz had been denied compensation, she did not address the

reasonable basis for her vaccine claim. Ms. Frantz’s counsel indicated that Ms.

Frantz did not personally incur any costs.5

The undersigned directed Ms. Frantz to address reasonable basis and

whether it can be gained or lost during the pendency of a case. Order, issued May

9, 2018. Ms. Frantz filed a memorandum in support of reasonable basis. Ms.

Frantz characterized reasonable basis as an objective inquiry that focuses on the

feasibility of a vaccine claim, rather than the claim’s likelihood of success. Pet’r’s

Memo., filed June 25, 2018, at 4-6, 8-9. In support of reasonable basis, Ms. Frantz

pointed to (1) her health before and after the vaccinations, (2) to some treating

physicians associating the vaccinations with her injuries, (3) the fact that a treating

physician filed a VAERS report, (4) that she suffers from a demyelinating disorder

of the central nervous system, (5) that many petitioners have received

compensation for demyelinating disorders, (6) that well-qualified experts provided

opinions in support of her claim, (7) absence of an alternative cause for her

injuries, (8) the logical sequence of events from vaccinations to her injuries, and

(9) the timing of the onset of symptoms supported by her experts. Ms. Frantz also

argued that an entitlement hearing was necessary to determine compensation, and

that reasonable basis existed through the hearing, because the bench ruling relied

heavily on Dr. Sriram’s oral testimony and use of visual MRI exhibits.

The Secretary filed a memorandum on July 6, 2018, arguing that Ms. Frantz

never had reasonable basis and that reasonable basis could not be gained or lost

during the pendency of a case. Using this view of reasonable basis, the Secretary

pointed to Ms. Frantz’s pre-existing lesions and the similarity to W.C., as evidence

5

Counsel filed an affidavit from his office manager, Susan Farrell, attesting that the firm

made ten unsuccessful attempts to obtain a statement from Ms. Frantz to comply with General

Order No. 9. Exhibit 61, filed Apr. 30, 2019. Ms. Farrell further attested that while Ms. Frantz

retained the firm she was not required to pay a retainer, to advance any litigation costs, and did

not incur any travel costs because she did not attend the entitlement hearing. Id.

12

that most of the fees and costs sought are “entirely superfluous.” Resp’t’s Memo.

at 16. Ms. Frantz filed a reply on July 27, 2018.6

To further develop the reasonable basis issue, an oral argument was

scheduled for March 20, 2019. In advance of the hearing, the undersigned issued

two orders directing the parties to address a non-precedential opinion in R.K., Fed.

Cir. No. 2018-1738, in which the Secretary had taken the position that reasonable

basis can be gained or lost during the pendency of a case. Orders, issued Mar. 12

& 15, 2019. The Secretary advised by informal communication that he was

changing his position in this case to conform with the position articulated in R.K.

Thus, the oral argument would no longer need to address whether reasonable basis

could be gained or lost during the pendency of case. The oral argument was held

as scheduled.

On April 30, 2019, Ms. Frantz filed a supplemental motion for attorneys’

fees and costs. The motion requested $25,537.47 in attorneys’ fees and costs for

the memoranda filed regarding reasonable basis and the oral argument. On May

10, 2019, the Secretary filed a response to the supplemental motion opposing an

award based on lack of reasonable basis. In her reply, Ms. Frantz reiterated her

arguments in favor of reasonable basis.

Ms. Frantz’s fee application is now ripe for adjudication. The analysis has

two parts. The first part is whether Ms. Frantz is eligible for any award of

attorneys’ fees and costs (section II and III below). Because Ms. Frantz is eligible

for some (but not all) of her attorneys’ fees and costs, the second part is

determining a reasonable amount of compensation (section IV below).

II. Standards for Adjudicating Eligibility for

An Award of Attorneys’ Fees and Costs

Petitioners who have not been awarded compensation are eligible for an

award of attorneys’ fees and costs when “the petition was brought in good faith

and there was a reasonable basis for the claim.” 42 U.S.C. § 300aa—15(e)(1). As

the Federal Circuit has stated, “good faith” and “reasonable basis” are two separate

elements that must be met for a petitioner to be eligible for attorneys’ fees and

6

This filing mainly addressed positions the Secretary later changed and, therefore, it is

not relevant to the determination of this motion.

13

costs. Simmons v. Secʼy of Health & Human Servs., 875 F.3d 632, 635 (Fed. Cir.

2017).

“Good faith” is a subjective standard. Id.; Hamrick v. Secʼy of Health &

Human Servs., No. 99-683V, 2007 WL 4793152, at *3 (Fed. Cl. Spec. Mstr. Nov.

19, 2007). A petitioner acts in “good faith” if he or she honestly believes that a

vaccine injury occurred. Turner v. Secʼy of Health & Human Servs., No. 99-544V,

2007 WL 4410030, at * 5 (Fed. Cl. Spec. Mstr. Nov. 30, 2007).

In contrast to good faith, reasonable basis is purely an objective evaluation

of the weight of the evidence. Simmons, 875 F.3d at 636. Because evidence is

“objective,” the Federal Circuit’s description is consistent with viewing the

reasonable basis standard as creating a test that petitioners meet by submitting

evidence. See Chuisano v. Secʼy of Health & Human Servs., No. 07-452V, 2013

WL 6234660, at *12-13 (Fed. Cl. Spec. Mstr. Oct. 25, 2013) (explaining that

reasonable basis is met with evidence), mot. for rev. denied, 116 Fed. Cl. 276

(2014).

The Federal Circuit and judges of the Court of Federal Claims have provided

some guidance as to what reasonable basis is not. A petition based purely on

“unsupported speculation,” even speculation by a medical expert, is not sufficient

to find a reasonable basis. Perreira v. Secʼy of Health & Human Servs., 33 F.3d

1375, 1377 (Fed. Cir. 1994). The background to Perreira comes from a 1991

decision denying compensation. The Perreiras alleged that a 1982 administration

of the diphtheria-pertussis-tetanus (“DTP”) vaccine harmed their daughter, Carly.

Initially, the Perreiras maintained that Carly started having seizures four days after

the second dose of DTP, based upon the testimony of Carly’s mother. The former

Chief Special Master found that Ms. Perreira’s testimony was not correct and

found, instead, that the seizures started 20 days after the second dose of DTP.

Perreira v. Sec’y of Health & Human Servs., No. 90-847V, 1991 WL 117740, at

*1 & n.2 (Cl. Ct. Spec. Mstr. June 13, 1991).

Given this sequence of events, the Perreiras attempted to establish a

significant aggravation claim. This alternative claim was based upon the sequence

that two weeks after the third dose of DTP, Carly had more seizures. The former

Chief Special Master rejected the Perreiras’ claim because there was no support for

their expert’s opinion that DTP causes harm that would first appear two weeks

later. Id.

After the entitlement proceedings concluded, the Perreiras sought an award

for their attorneys’ fees and costs. The former Chief Special Master found that the

14

Perreiras had a reasonable basis for filing their petition. Perreira v. Sec’y of Health

& Human Servs., No. 90-487V, 1992 WL 164436, at *2 (Cl. Ct. Spec. Mstr. June

12, 1993). The decision does not state the reason for finding reasonable basis.

The former Chief Special Master explicitly found that the reasonable basis

ceased after the expert submitted a report, noting that the expert’s theory

“amounted to his own unsupported speculation[,]” and that the Perreiras’ attorney

should have recognized that the expert’s theory “was legally insufficient to

establish causation.” The former Chief Special Master also stated that the

Perreiras’ attorney recognized that this case “was a ‘bad case.’” Id. at *1-2.

The Perreiras filed a motion for review of the denial of a portion of the

attorneys’ fees and costs. The Court of Federal Claims found that the former Chief

Special Master’s determination that the case lacked a reasonable basis was not

arbitrary. The Court of Federal Claims rejected the petitioners’ arguments,

including an argument that “counsel had an absolute right to rely on the expert’s

opinion in pursuing the case.” Perreira v. Sec’y of Health & Human Servs., 27

Fed. Cl. 29, 33 (1992).

These decisions are the background for the Federal Circuit’s discussion of

“reasonable basis” in its Perreira opinion. The Federal Circuit affirmed the former

Chief Special Master’s decision that the Perreiras lacked a reasonable basis to

proceed to a hearing, despite an expert report, because “the expert opinion was

grounded in neither medical literature nor studies.” The Federal Circuit explained

that “[t]he special master did not require counsel to verify the validity of the

expert’s opinion, but only required the opinion to be more than unsupported

speculation.” Perreira, 33 F.3d at 1377.

Perreira demonstrates that special masters enjoy discretion to find that a

claim lacked a reasonable basis when the evidence on which the petitioners relies

(there, an expert’s report) is rooted in unsupported speculation. In this context, the

Federal Circuit seemed to give some teeth to the term “reasonable basis.” The

Federal Circuit declared: “Congress must not have intended that every claimant,

whether being compensated or not under the Vaccine Act, collect attorneys’ fees

and costs by merely having an expert state an unsupported opinion.” 33 F.3d at

1377.

Another example of a case exemplifying a deeper than skin-deep look at

reasonable basis is an early case from the Vaccine Program, Murphy v. Secʼy of

Health & Human Servs., No. 90-882V, 1991 WL 74931 (Fed. Cl. Spec. Mstr. Apr.

25, 1991). Today, Murphy is often cited as a well-known case in which a special

15

master weighed the value of medical records created contemporaneously with the

events the medical records described against the value of affidavits created many

years later. The special master found that the medical records were more reliable,

1991 WL 74931 at *5, and the Court of Federal Claims ruled that this finding was

not arbitrary. 23 Cl. Ct. 726, 734 (1991), affʼd, 968 F.2d 1226 (Fed. Cir. 1992).

Under the representations presented in the contemporaneously created medical

records, the petitioners in Murphy were not entitled to compensation.

A less recognized aspect to Murphy is the ensuing motion for attorneys’ fees

and costs, which is more relevant to the case at hand. Although the special

master’s 1993 decision denying an award of attorneys’ fees and costs is

unpublished, the opinion on a motion for review states the special master found a

lack of reasonable basis because “the medical records and other written records

contradict the claims brought forth in the petition.” 30 Fed. Cl. 60, 61 (1993).

Upon a motion for review, the petitioners argued that the special master abused his

discretion in denying attorneys’ fees and costs. More specifically, the petitioners

argued that “because they submitted expert opinion to support their claim, they had

a reasonable basis for their case as a matter of law.” Id. at 62.

The Court, however, rejected the petitioners’ argument and ruled that the

special master was not arbitrary in finding a lack of reasonable basis. The Court

reasoned that an expert report premised on unreliable assertions does not confer

reasonable basis:

[The petitioners’] position assumes that special masters

rely upon expert testimony without determining whether

it is corroborated by the facts. This position is not

plausible, as expert testimony in and of itself does not

determine reasonableness. . .. [T]he expert opinion

submitted by petitioners was founded upon Mrs.

Murphy’s version of the events, a version found to be

unreliable by the special master.

Id. at 63.

Thus, two appellate authorities demonstrate that the presence of a report

from a retained expert, by itself, does not establish reasonable basis automatically.

These two appellate authorities also resolve a difference between the parties in

how to assess the evidence in the context of determining whether a reasonable

basis supports the claims set forth in the petition.

16

The disputed point concerns whether special masters should consider all the

evidence or only evidence favoring the petitioner. Although Ms. Frantz recognizes

that in determining whether petitioners have established entitlement to

compensation, special masters “may consider all relevant and reliable evidence.”

Pet’r’s Resp., filed June 25, 2018, at 20 (citing Vaccine Rule 8(b)(1)), she

advocates for a different approach in considering the question of reasonable basis.

In her view, “Case law regarding the reasonable basis analysis focuses on objective

support for petitioner’s claim, but does not often focus on objective evidence

submitted by respondent in defense of petitioner’s claim.” Id. (italics and

underlining in original). She further argues that special masters, in determining

reasonable basis, should not weigh competing evidence. Instead, special masters

should borrow from the summary judgment standard and evaluate the evidence in

the light most favorable to the petitioner. Id. at 20-21.

The Secretary takes a different view. Noting that Congress did not use the

term “summary judgment” in the context of reasonable basis, the Secretary

maintains that the summary judgment standard in the reasonable basis inquiry “is

fraught with problems.” Resp’t’s Resp., filed July 6, 2018, at 9.

Neither Perreira nor Murphy discussed a summary judgment standard.

Instead, in the original decisions from the special masters, the special masters

evaluated (or weighed) the evidence. In Perreira, the former Chief Special Master

stated the expert’s opinion “amounted to his own unsupported speculation,” 1992

WL 164436, at *2, and the Federal Circuit endorsed this view, commenting that

“the expert opinion was grounded in neither medical literature nor studies.” 33

F.3d at 1377. Similarly, in Murphy, the special master found that the expert’s

opinion did not provide a reasonable basis because the opinion was premised on a

sequence of events that did not match the special master’s finding of facts. 30 Fed.

Cl. at 61-63.

In the absence of any appellate authority requiring a summary judgment

standard, the undersigned does not construe the evidence in petitioner’s favor. An

objective weighing of the evidence is consistent with cases that have placed the

burden of establishing the petition’s reasonable basis on petitioners. Carter v.

Secʼy of Health & Human Servs., 132 Fed. Cl. 372, 379 (2017) (citing Woods v.

Secʼy of Health & Human Servs., 105 Fed. Cl. 148, 152 (2012) and McKellar v.

Secʼy of Health & Human Servs., 101 Fed. Cl. 297, 305 (2011)). However, the

petitioner’s burden is to establish the reasonable basis for the claims set forth in the

petition. This burden is not the same as the burden of establishing entitlement to

compensation. See Chuisano, 2013 WL 6234660, at *12-13.

17

III. Assessment of Reasonable Basis

To determine whether Ms. Frantz’s case passed the evidentiary threshold for

reasonable basis, the undersigned will divide her case into phases and evaluate the

evidence as of that period. In analyzing the evidence, the focus will be whether

reasonable basis (meaning evidence) supports “the claim for which the petition was

brought” — that the Tdap and hepatitis A vaccines caused Ms. Frantz to suffer a

demyelinating injury.

A. Before Dr. Tornatore’s First Report7

Ms. Frantz filed Dr. Tornatore’s first report, exhibit 36, on November 25,

2014. Until this date, the evidence primarily consisted of Ms. Frantz’s medical

records. In treating Ms. Frantz, many doctors presented a chronology of events in

which the doctors noted that Ms. Frantz received vaccinations shortly before she

started to manifest neurologic problems. Ms. Frantz has recited them. Pet’r’s

Resp., filed June 25, 2018, at 24-31. Most of these records do not support “the

claim for which the petition was brought” in that the treating doctors do not say

anything about causation. See Chuisano, 116 Fed. Cl. at 287 (a “[t]emporal

proximity is necessary, but not sufficient” to establish a reasonable basis) (citation

omitted). Similarly, medical records in which a doctor records a medical history in

which the historian reports an adverse reaction are not helpful. For example, Ms.

Frantz identified a December 6, 2010 record from an ophthalmologist as indicating

that she had “a severe reaction to the Hep A and Addisol vaccination.” Exhibit 4 at

32, cited in Pet’r’s Resp., filed June 25, 2018, at 28. But, this quotation, while

accurate, is from the history section of the medical report. The doctor did not

comment about any link between the vaccinations and any ophthalmologic injury

in his impression. Id. at 34. This report does not assist in the evaluation of

reasonable basis because Congress dictated that the special masters may not make

findings regarding entitlement to compensation “based on the claims of a petitioner

alone, unsubstantiated by medical records or by medical opinion.” 42 U.S.C.

§ 300aa–13. Here, the layperson’s recitation of “a severe reaction” is not elevated

in status simply because a doctor memorialized it.

However, at least one record from the treating doctors is supportive. In Ms.

Frantz’s second trip to an emergency room within a week of the vaccination, the

7

Although this section discusses the evidence before Ms. Frantz filed Dr. Tornatore’s

report, the filing of an expert report later in a case can supply the reasonable basis to file the

petition. See Hiland v. Sec’y of Health & Human Servs., No. 10-491V, 2015 WL 4985247, at *2

(Fed. Cl. Spec. Mstr. July 31, 2015).

18

doctor from the emergency room stated that his diagnostic impression was “Central

nervous system reaction to hepatitis A vaccine.” Exhibit 11 at 828. Unlike the

ophthalmologist’s report just discussed, this opinion is from the emergency room

doctor. As such, it is a “medical record” supporting the claim that the vaccinations

caused Ms. Frantz to suffer a demyelinating injury.

In this context, Ms. Frantz also relies upon a doctor’s presentation of Ms.

Frantz’s case to appropriate government officials through the Vaccine Adverse

Events Reporting System (VAERS). See Pet’r’s Resp., filed June 25, 2018, at 27

and 32. Lauren Kaup did file such a VAERS report on September 16, 2010.

Exhibit 21 at 2.8 Whether the filing of a VAERS report contributes to the

evaluation of reasonable basis varies. Compare Santacroce on behalf of J.R. v.

Sec’y of Health & Human Servs., No. 15-555V, 2018 WL 405121, ___ Fed. Cl.

___, at *8 (Jan. 5, 2018) (noting special master had erred in failing to credit the

submission of a VAERS report) with E.M. by McCoy v. Sec'y of Health & Human

Servs., No. 17-875V, 2018 WL 6254274, at *7 (Fed. Cl. Spec. Mstr. Oct. 15, 2018)

(“It is otherwise well established in the Program that VAERS data is not persuasive

with regard to any causal connection between vaccination and injury, and

petitioners cannot rely on such to establish reasonable basis for a claim”). Another

option is to look at VAERS reports on a “case by case basis.” McKellar v. Sec'y of

Health & Human Servs., No. 09-841V, 2012 WL 362030, at *11 n.15 (Fed. Cl.

Spec. Mstr. Jan. 13, 2012), mot. for rev. granted on other grounds, 2012 WL

1884703 (Fed. Cl. May 3, 2012).

Here, the value of Dr. Kaup’s VAERS report is unclear. Dr. Kaup recorded

the date of the vaccinations (August 6, 2010) and the onset of the adverse event

(August 7, 2010). Exhibit 21 at 2 (boxes 10 and 11). Dr. Kaup also described Ms.

Frantz’s clinical course in approximately three sentences. Id. (box 7). However,

Dr. Kaup did not state explicitly that she thought the vaccinations caused the ataxia

or weakness. Thus, whether Dr. Kaup intended to communicate that she suspected

a causal relationship cannot be determined directly.

In sum, this evidence weighs in favor of a finding that Ms. Frantz had

“objective” support for a claim that the vaccinations caused her to suffer an injury

in her central nervous system. Two related points warrant emphasis. First, the

objective evidence is not particularly strong. The objective evidence consists

primarily of the emergency room doctor’s impression of a “[c]entral nervous

8

Although the VAERS report does not provide information about Dr. Kaup, other

material shows that she is a specialist in critical care. See, e.g., exhibit 9 at 135.

19

system reaction to hepatitis A vaccine.” As one piece of evidence, this report is

relatively weak. The doctor offered this opinion relatively early in the course of

Ms. Frantz’s illness, before the extent of her demyelinating injury was detected on

an MRI. Further, it is not clear that the doctor’s reference to “reaction”

encompassed the disease with which Ms. Frantz was eventually diagnosed,

multiple sclerosis.

Second, there does not appear to be any evidence pointing against a finding

of entitlement. For example, there appears to be no treating doctor who initially

rejected the proposition that a vaccine could have injured Ms. Frantz. And, at this

stage of the case, the Secretary has not introduced any contrary evidence. Thus,

the record, considered as a whole, balances in favor of a finding a reasonable basis.

B. Dr. Tornatore’s First and Second Reports

Although Dr. Tornatore was instructed to answer various questions, his first

report (exhibit 35) did not answer all of them. He provided additional information

in his second report (exhibit 38). Thus, these reports are treated together.

These reports start to show the shakiness of Ms. Frantz’s claim that the

vaccinations caused her a neurologic problem. Before Ms. Frantz filed Dr.

Tornatore’s first report, Ms. Frantz knew that the time between the vaccinations on

August 6, 2010 and Ms. Frantz’s dizziness on August 7, 2010 was an issue.

Resp’t’s Rep., filed May 1, 2014, at 9-10. Nevertheless, Dr. Tornatore did not

present a coherent explanation for how the sequence of events supported a finding

of causation. In his first report, he stated that an appropriate interval between

vaccination and the manifestation of the symptoms of ADEM was 2-30 days.

Exhibit 35. However, despite being instructed to identify the initial manifestation

of Ms. Frantz’s neurologic injury by exhibit number and page number

(Instructions, issued June 16, 2014, at ¶ 6(a)(iii)), Dr. Tornatore did not. Instead,

he opined that her symptoms started “several days” after the vaccination. Exhibit

35 at 58.

Dr. Tornatore’s statement about “several days” was not credible. Just three

days after vaccination, Ms. Frantz’s mother reported that her daughter had been

off-balance, dizzy, and sluggish since August 7, 2010, which was the day after

vaccination. Dr. Tornatore seemed to disregard these symptoms without any

explanation.

When instructed a second time to say when Ms. Frantz first manifested a

neurologic injury, Dr. Tornatore was more definitive. He identified the dizziness

20

and sluggish on August 7, 2010 as the initial manifestation. Exhibit 38 at 6. This

opinion is credible.

However, a one-day interval between the vaccinations and the dizziness

made Dr. Tornatore’s opinion internally inconsistent. His first report presented his

opinion that two days was the minimal appropriate interval, but his second report

said that the interval for Ms. Frantz was one day. It is important to recognize that

this inconsistency comes from what only Dr. Tornatore wrote. The inconsistency

is not due to the Secretary presenting any contrary evidence.

The one-day onset of symptoms is separate from the issue about the

formation of lesions that Ms. Frantz’s first MRI detected. From Dr. Tornatore’s

experience in W.C. and from Ms. Frantz’s attorney’s experience in W.C., both

were on notice that a finding of non-enhancement probably meant that the lesions

did not develop after vaccination. Dr. Tornatore’s first report recited that the

August 12, 2010 MRI showed one enhancing and two non-enhancing lesions.

Exhibit 36 at 5, 56. However, Dr. Tornatore did not address how vaccines

administered on August 6, 2010 could cause two lesions that appeared as non-

enhanced lesions six days later.

On balance, Dr. Tornatore’s first two reports were poor. They failed to

engage the meaningful issues. However, the reports were not so deficient that they

cause Ms. Frantz to lose the reasonable basis that the emergency room doctor’s

report had conferred upon her.

C. Dr. Tornatore’s Third Report

After Dr. Tornatore’s first two reports, the Secretary began to present

evidence that further undermined Dr. Tornatore’s opinions. Dr. Sriram’s first

report stated that the lesion on Ms. Frantz’s medulla probably caused her ataxia,

which was noted in medical records on August 12, 2010. Exhibit A at 3 (citing

exhibit 9 at 841). But, Dr. Sriram opined that the process for creating a lesion and

for the lesion to go from enhanced to non-enhanced would take longer than six

days. Id. at 6. Dr. Sriram did not cite Cotton in his first report.

Thus, by the time he wrote his third report, Dr. Tornatore knew that the

duration of lesion enhancement was a foundation for Dr. Sriram’s opinion that Ms.

Frantz’s timeline did not fit. However, Dr. Tornatore did not challenge Dr.

Sriram’s opinion about the duration of lesion enhancement, leaving Dr. Sriram’s

opinion unrebutted. See exhibit 39.

21

Dr. Tornatore’s response was to change his opinion in a different respect.

As previously discussed, Dr. Tornatore initially proposed that the appropriate

temporal interval between vaccination and ADEM was 2-30 days. Exhibit 36 at

57. Now, Dr. Tornatore indicated that because Ms. Frantz was previously

vaccinated against diphtheria, the August 6, 2010 vaccination was a “rechallenge,”

meaning that her immune response would be “brisk.” Dr. Tornatore continued:

“Indeed the Institute of Medicine recognized that injury from a vaccine can occur

1-3 days following vaccination if an individual has been exposed to a vaccine

previously.” Exhibit 39 at 3.

Dr. Tornatore’s opinion here is problematic for several reasons. First, and

least significantly, as an expert who has appeared in many Vaccine Program cases,

Dr. Tornatore was almost certainly aware of the 2012 IOM report before he wrote

his first report in this case. Dr. Tornatore also should have been aware that the

August 6, 2010 diphtheria vaccination was a booster vaccination when he wrote his

first report. However, Dr. Tornatore did not present any opinion about rechallenge

then. Instructions, issued June 16, 2014, at ¶ 7(a)(ii)(1) (expert instructions stating

that “petitioner’s expert should consider whether [Ms. Frantz’s] case contains

evidence showing: 1. Challenge-rechallenge”).

Second, Dr. Tornatore errs in how he reports what the IOM stated. Dr.

Tornatore extracts one sentence from a section titled “Latency Between Antigen

Exposure and Peak Adaptive Immune Response.” Exhibit 39, tab D at 57

(capitalization changed). The IOM explained that after exposure to an antigen, T

cells and B cells move through a “lag phase, logarithmic phase, and plateau

phase.” Id. In the context of describing the immune system’s response upon a

reexposure, the IOM stated “The lag phase is generally 1 to 3 days; the logarithmic

phase of the secondary antibody response occurs over the next 3 to 5 days.” Id. In

presenting his opinion, Dr. Tornatore discussed only the lag phase, a phase that is

“characterized by the initial activation of B and T cells, . . . and the trigger[ing] the

cells’ differentiation into effector and memory cells.” Id. Dr. Tornatore does not

discuss the logarithmic phase, the phase during which B cells and T cells multiply

and respond to the antigen. Dr. Tornatore provided no information about how the

damage can happen in the first day of the lag phase. Furthermore, the IOM did not

discuss, in this section, when injuries due to vaccination occur.

Third, even if the IOM could be construed as saying some vaccine injuries

could occur within one day, Dr. Tornatore failed to discuss a critical issue for Ms.

Frantz, how fast demyelinating lesions could form. Dr. Sriram already had opined

that the sequence of events in Ms. Frantz’s case occurred too quickly for the

vaccinations to have caused her dizziness on August 7, 2010, or the lesion detected

22

on the August 12, 2010 MRI. Exhibit A at 7. Dr. Tornatore’s report did not

directly refute Dr. Sriram’s opinion on these points. Dr. Tornatore did not fill in

this omission and the lack of meaningful dispute ultimately led to a finding that

Ms. Frantz was not entitled to compensation.

At this point, the reasonable basis for Ms. Frantz’s continued litigation is

doubtful. She is relying upon an expert, Dr. Tornatore, who has written three poor

reports. Nevertheless, the benefit of the doubt is extended to her and reasonable

basis is extended through Dr. Tornatore’s third report.9

D. Dr. Sriram’s third report and Dr. Tornatore’s fourth report

The Secretary obtained the MRIs for Dr. Sriram so that he could review the

actual images, not just the reports about the MRIs. Order, issued Aug. 28, 2015.

Based upon his review of the MRIs, Dr. Sriram stated that two lesions were non-

enhancing. Dr. Sriram cited Cotton to establish the duration of enhancement.

Putting the non-enhancement of Ms. Frantz’s lesions together with the duration of

enhancement from Cotton, Dr. Sriram concluded that the vaccinations could not

have caused the lesions. Ms. Frantz must have had those lesions before she was

vaccinated. Exhibit D; see also exhibit 9 at 1385 (radiologist’s report).

After the Secretary filed this report, the parties discussed the case in a

December 15, 2015 status conference. The ensuing order stated Ms. Frantz

“probably cannot prevail on a claim that vaccination caused her neurologic

condition,” and cited W.C. v. Sec’y of Health & Human Servs., 704 F.3d 1352

(Fed. Cir. 2013), in support. Order, issued Dec. 15, 2015. This assessment, which

Vaccine Rule 5 permits, should have warned Ms. Frantz about the continued

prosecution of the claim set forth in her petition. See Rehn v. Sec’y of Health &

Human Servs., No. 14-1012V, 2017 WL 1011487, at *6 (Fed. Cl. 2017) (ruling

that the special master was not arbitrary in finding no reasonable basis for

successor counsel to proceed with a case after the special master had warned the

first counsel about the case’s weaknesses); Hamilton v. Sec’y of Health & Human

Servs., No. 14-785V, 2018 WL 2772197, at *5 (Fed. Cl. Spec. Mstr. April 12,

2018) (finding reasonable basis in an autism case until the case was stayed pending

the outcome of certain appeals).

Ms. Frantz continued to pursue her case and she certainly possessed the right

to prosecute her case. This pursuit, however, was in the face of an assessment that

9

This extension makes Ms. Frantz eligible for a relatively small additional amount of

attorneys’ fees and costs.

23

based upon Federal Circuit precedent, she was unlikely to prevail. Ultimately, her

efforts did not lead to evidence sufficient to show that she had a reasonable basis to

maintain her claim.

The fourth report from Dr. Tornatore does not help Ms. Frantz. Dr.

Tornatore essentially says that if Ms. Frantz had received a triple dose of the agent

that creates contrast, gadolinium, and if an MRI were performed with

“magnetization transfer contrast and delayed imaging,” then the lesions that had

appeared as non-enhanced (meaning old) would have appeared as enhanced

(meaning new). Exhibit 40 at 1. However, Ms. Frantz did not receive a triple dose

of gadolinium. Thus, Dr. Tornatore has no basis to predict how Ms. Frantz would

respond to a hypothetical test. In other words, Dr. Tornatore’s fourth report is

speculation and expert speculation is the antithesis of reasonable basis.

The reasonable basis that supported the claim in Ms. Frantz’s petition ended

with the submission of Dr. Tornatore’s fourth report. The fourth report cemented

the failure of Ms. Frantz and Dr. Tornatore to answer the fundamental point that

Dr. Sriram had raised based upon Cotton: Ms. Frantz probably had lesions before

she was vaccinated. Arguably, because Dr. Tornatore’s fourth report contributed

so little to Ms. Frantz’s case, the line could have been drawn before the filing of

Dr. Tornatore’s fourth report. This view would probably track more closely with

the value of the evidence. However, it also seems fair to allow Ms. Frantz a

limited opportunity to respond to Dr. Sriram’s third report, which had added

Cotton. Once Ms. Frantz took this opportunity and received another weak report

from Dr. Tornatore, Ms. Frantz continued to prosecute her case without reasonable

basis.

E. Remainder of the Case

In finding that Ms. Frantz did not submit evidence after Dr. Sriram’s second

report to possess a reasonable basis to continue to prosecute her claim, the

undersigned has considered the entire record. This material includes, in

chronological order, Dr. Forsthuber’s first report (exhibit F), Dr. Tornatore’s fifth

report (exhibit 42), Dr. Steinman’s first report (exhibit 43), Dr. Forsthuber’s

second report (exhibit G), and Dr. Steinman’s second report (exhibit 56).

Collectively, these reports do not address the central issue — the meaning of two

non-enhanced lesions on Ms. Frantz’s August 12, 2010 MRI.

The undersigned has also considered the April 11, 2017 order for pre-trial

briefs and the May 1, 2017 status conference to discuss the expected content of

those briefs. The undersigned raised the issue about the reasonable basis to

24

proceed to the hearing in light of the similarity to W.C. Although the undersigned

is not aware that any appellate tribunal has required a special master to warn

attorneys that a case may not have a reasonable basis, the undersigned was

attempting to alert Ms. Frantz’s attorneys to proceed with caution.

Regardless, Ms. Frantz and her attorneys continued by filing a pre-hearing

brief on July 27, 2017. This brief did not identify errors in Dr. Sriram’s opinion

that, based upon Cotton’s investigation into the duration of lesion enhancement

and the findings on Ms. Frantz’s August 12, 2010 MRI, Ms. Frantz most likely had

lesions in her brain before the allegedly causal vaccinations. See Pet’r’s Prehear’g

Br. at 53-55. In a footnote, Ms. Frantz discussed two other MRIs — one from

August 27, 2010 and the other from September 14, 2010. Id. at 55 n.34. But,

those MRIs are not the critical MRI. Ms. Frantz ends this footnote with the

statement that: “The MRI findings in [her] case illustrate the arbitrariness of the

findings in W.C.”

This statement is not persuasive for at least two reasons. First, Ms. Frantz

did not produce any evidence in the form of an expert’s opinion that called into

question the validity of the conclusions Cotton reached. Second, by describing the

factual findings in W.C. as “arbitrary,” Ms. Frantz seems to be ignoring or

disregarding binding Federal Circuit precedent that found the factual findings in

W.C. were not arbitrary. In short, it appears that Ms. Frantz’s attorneys were not

evaluating the entire record (see 42 U.S.C. § 300aa–13(a)) dispassionately.

The zealousness with which Ms. Frantz’s attorneys may have represented

her is not relevant to determining whether a reasonable basis supports the claims

set out in the petition. For example, in Perreira, the petitioner’s attorney argued

that his ethical obligations to represent his client zealously required him to proceed

to a hearing. However, the Federal Circuit ruled that “counsel's duty to zealously

represent their client does not relieve them of their duty to the court to avoid

frivolous litigation.” Perreira, 33 F.3d at 1377.

Likewise, in Simmons, the petitioner’s attorney argued that an ethical duty

also compelled the submission of a petition before the expiration of the time set

forth in the statute of limitation. But, the Federal Circuit held that “objective”

evidence — not the actions of counsel — determine whether reasonable basis

supports the claims set forth in the petition. Simmons, 875 F.3d at 635-36.

While Perreira and Simmons (both originating from the Vaccine Program)

are controlling precedent, distinguishing between the evidence and counsel’s views

of that evidence is consistent with the Federal Circuit’s jurisprudence in

25

interpreting a fee-shifting statute for patent litigation. Pursuant to 35 U.S.C. § 285,

district courts may award attorneys’ fees and costs for exceptional cases. See

Octane Fitness, LLC v. ICON Health & Fitness, Inc., 572 U.S. 545 (2014). In

affirming a trial court’s finding that a case was exceptional, the Federal Circuit

declared: “We agree, as a general matter, that the extent of a party’s pre-suit

investigation or how fervently it believed in its allegations does not affect the

objective strength of that party’s litigating position.” Nova Chemicals Corp. v.

Dow Chemical Co., 856 F.3d 1012, 1018 (Fed. Cir. 2017) (affirming award of

attorneys’ fees), cert. denied, 138 S.Ct. 485 (2017). By the time Ms. Frantz was

submitting her pre-hearing brief, she should have evaluated the “objective”

strength of her position and realized that she was not likely to prevail.

After Ms. Frantz filed her pre-hearing brief, the Secretary filed another

report from Dr. Sriram that reinforced the strength of the Secretary’s position and

knocked more holes in Ms. Frantz’s claim that the vaccinations caused her

demyelinating condition. Dr. Sriram disclosed an opinion that the August 12, 2010

MRI contained “black hole” lesions. Exhibit H at 2-3. Black holes exist only after

a process that takes at least 15-27 days. Id.; Tr. 277-82.

The undersigned’s bench ruling and memorialization of that ruling

emphasized the persuasiveness of Dr. Sriram’s opinion regarding black holes. Tr.

566-67; 2017 WL 4899415. In arguing in support of a finding of reasonable basis,

Ms. Frantz seizes this finding. To her, because the dispositive evidence was not

presented until exhibit H and reinforced during the hearing, she must have had a

reasonable basis through the hearing.

While understandable, this argument is mistaken. See AFGE Local 3599 v.

Equal Employment Opportunity Commission, 920 F.3d 794 (Fed. Cir. 2019)

(requiring fee adjudicator to set forth reasons for denial of fees). The

undersigned’s worries about the evidentiary basis for Ms. Frantz’s claim began

much earlier. The undersigned disclosed concerns about the weakness of Ms.

Frantz’s objective evidence in the status conference following the filing of Dr.

Sriram’s third report. Order, issued Dec. 15, 2015.10 As discussed above, Ms.

Frantz had multiple opportunities to improve the objective strength of her position

but did not. While Dr. Sriram’s opinion regarding black holes was a primary basis

for finding that Ms. Frantz was not entitled to compensation, this opinion is not a

10

While Dr. Sriram had not disclosed an opinion about Cotton in his first report (exhibit

A), he had reviewed the MRI images between writing his first report and his third report. See

order, issued Aug. 28, 2015.

26

primary basis for finding that Ms. Frantz lacked a reasonable basis to continue

litigation after March 16, 2016.11

Similarly, Ms. Frantz argued that W.C. should not prevent a finding that

reasonable basis supported her claim throughout the duration of the claim because

the Vaccine Program should recognize that science could change. Oral argument,

Mar. 20, 2019, Tr. 15. This argument could be persuasive when science and

knowledge changes. Here, Ms. Frantz did not controvert the 2003 Cotton study

about the duration of lesion enhancement. When Dr. Tornatore responded to Dr.

Sriram’s discussion of Cotton, Dr. Tornatore added three articles but all these

articles were published before Cotton. See exhibit 40, Tabs A-C. Thus, Ms.

Frantz’s case does not present a situation where the advancement of knowledge

causes a different result on the question of whether a vaccine caused an illness.

The evidence in Ms. Frantz’s case regarding the duration of lesion

enhancement and the presence of non-enhanced lesions on an MRI taken shortly

after vaccination closely resembles the evidence in W.C. Although Ms. Frantz was

given opportunities to develop evidence that would persuasively show her case

differed from W.C., she did not. As explained above, by March 16, 2016, the

objective evidence no longer supported the claim set forth in her petition.12

11

A calendar might clarify this point. In describing Ms. Frantz’s August 12, 2010 lesions

as non-enhanced, Dr. Sriram seemed to be suggesting that they were at least three weeks old

because the median duration of enhancement is two weeks. Exhibit A at 7, exhibit D at 2. This

chronology means that Ms. Frantz had lesions in July 2010. The existence of lesions in July

2010, is sufficient to ground Dr. Sriram’s opinion that the vaccinations on August 6, 2010 did

not cause Ms. Frantz’s demyelinating condition.

When Dr. Sriram disclosed his opinion that two of the August 12, 2010 lesions were

black holes (exhibit H), Dr. Sriram was proposing a chronology that placed the creation of those

lesions back even earlier. Because of the duration of the process for creating black holes, the

black holes detected on August 12, 2010 meant that Ms. Frantz’s lesions may have been present

in June.

12

Again, Ms. Frantz’s petition alleged that the vaccines caused her demyelinating injury.

Because the Vaccine Act allows for an award of attorneys’ fees and costs when there is

“reasonable basis” for the “claim for which the petition was brought,” the foregoing analysis has

focused on the objective basis for the claim that the vaccines caused Ms. Frantz’s demyelination.

42 U.S.C. § 300aa-15(e)(1)(B). Ms. Frantz’s causation-in-fact claim necessarily assumes that

she did not have demyelination before the vaccination.

Conceivably, after Dr. Sriram had presented persuasive evidence that Ms. Frantz had

lesions before vaccination, she could have amended her petition to allege that the vaccination

significantly aggravated her pre-existing and undiagnosed multiple sclerosis. See Quackenbush-

Baker v. Sec’y of Health & Human Servs., No. 14-1000V, 2018 WL 1704523 (Fed. Cl. Spec.

27

As discussed below, this finding carries a consequence that some work Ms.

Frantz’s attorneys performed and some work by Dr. Tornatore and Dr. Steinman

are not compensable through the Vaccine Program. This consequence is necessary

because Congress required non-prevailing petitioners to establish a reasonable

basis to be eligible for an award of attorneys’ fees and costs. Congress’s

imposition of a reasonable basis standard means that “fee denials are expected to

occur.” Chuisano v. Sec’y of Health & Human Servs., 116 Fed. Cl. 276, 286

(2014).

IV. Amount of Attorneys’ Fees and Costs

After the determination of when reasonable basis supported the claim set

forth in the petition, the process for determining a reasonable amount of attorneys’

fees and costs is relatively straightforward. In light of the Secretary’s lack of

objection to the amount of attorneys’ fees and costs, the undersigned has reviewed

the fee application for its reasonableness. See McIntosh v. Secʼy of Health &

Human Servs., 139 Fed. Cl. 238 (2018).

The Vaccine Act permits an award of reasonable attorney’s fees and costs.

§15(e). The Federal Circuit has approved the lodestar approach to determine

reasonable attorneys’ fees and costs under the Vaccine Act. This is a two-step

process. Avera v. Sec’y of Health & Human Servs., 515 F.3d 1343, 1348 (Fed.

Cir. 2008). First, a court determines an “initial estimate … by ‘multiplying the

number of hours reasonably expended on the litigation times a reasonable hourly

rate.’” Id. at 1347-48 (quoting Blum v. Stenson, 465 U.S. 886, 888 (1984)).

Second, the court may make an upward or downward departure from the initial

calculation of the fee award based on specific findings. Id. at 1348. Here, because

the lodestar process yields a reasonable result, no additional adjustments are

required. Instead, the analysis focuses on the elements of the lodestar formula, a

reasonable hourly rate and a reasonable number of hours.

A. Reasonable Hourly Rates

Under the Vaccine Act, special masters, in general, should use the forum

(District of Columbia) rate in the lodestar calculation. Avera, 515 F.3d at 1349.

There is, however, an exception (the so-called Davis County exception) to this

general rule when the bulk of the work is done outside the District of Columbia

and the attorneys’ rates are substantially lower. Id. (citing Davis Cty. Solid Waste

Mstr. Mar. 14, 2018). However, for whatever reason, she did not. Thus, this decision does not

evaluate the reasonable basis for a claim that Ms. Frantz did not assert.

28

Mgmt. and Energy Recovery Special Serv. Dist. v. U.S. Envtl. Prot. Agency, 169

F.3d 755, 758 (D.C. Cir. 1999)). In this case, all the attorneys’ work was done

outside of the District of Columbia.

The undersigned has reviewed the requested rates and finds them largely to

be reasonable and in conformance with what the Conway Homer firm attorneys

and paralegals have previously been awarded for their work in the Vaccine

Program. See Harris v. Sec’y of Health & Human Servs., No. 16-528V, 2018 WL

5816741, at *1 (Fed. Cl. Spec. Mstr. Sept. 24, 2018); McSorley v. Sec'y of Health

& Human Servs., No. 14-919V, 2018 WL 4390500, at *1 (Fed. Cl. Spec. Mstr.

Aug. 16, 2018).

B. Reasonable Number of Hours

The second factor in the lodestar formula is a reasonable number of hours.

Reasonable hours are not excessive, redundant, or otherwise unnecessary. See

Saxton v. Sec’y of Health & Human Servs., 3 F.3d 1517, 1521 (Fed. Cir. 1993).

The Secretary also did not directly challenge any of the requested hours as

unreasonable.

From the inception of the case until March 16, 2016, the attorneys’ and

paralegals’ invoices total $88,255.50. Within this period, almost all of the billing

is reasonable.

Some reduction is required for work considered administrative. Billing for

clerical and other secretarial work is not permitted in the Vaccine Program.

Missouri v. Jenkins, 491 U.S. 274, 288 n.10 (1989); Bennett v. Dep’t of Navy, 699

F.2d 1140, 1145 n.5 (Fed. Cir. 1983); Guy v. Sec'y of Health & Human Servs., 38

Fed. Cl. 403, 407-08 (1997); Rochester v. United States, 18 Cl. Ct. 379, 387 (1989)

(denied an award of fees for time billed by a secretary and found that “[these]

services … should be considered as normal overhead office costs included within

the attorneys’ fees rates”). Filing documents is a clerical task for which attorneys

should not charge. See Guerrero v Secʼy of Health & Human Servs., No. 12-689V,

2015 WL 3745354, at *6 (Fed. Cl. Spec. Mstr. May 22, 2015) (citing cases), mot.

for rev. den’d in relevant part and granted in non-relevant part, 124 Fed. Cl. 153,

160 (2015), app. dismissed, No. 2016-1753 (Fed. Cir. Apr. 22, 2016).

In addition, the attorneys duplicated work, although this duplication was

relatively rare. See, e.g., entries for 11/14/2014, 5/14/2015.

Finally, a law clerk seems to have spent a relatively lengthy amount of time

reviewing medical records. For example, although exhibit 9 is a critical medical

29

whose length exceeds two thousand pages, the law clerk spent more than 40 hours

on this one exhibit. See entries, starting 7/1/2013. Even given the law clerk’s

relatively low hourly rate due, in part, to the law clerk’s inexperience, it appears

that the amount of time was excessive. It may be the case that additional guidance

from the experienced attorneys will help the law clerk learn how to review and to

summarize medical records efficiently.

In an attempt to administer “rough justice” the undersigned shall reduce the

amount of attorneys’ fees awarded by $750.00. Accordingly, a reasonable amount

of attorneys’ fees during the portion of the entitlement phase of the case in which

reasonable basis supported the petition is $87,505.50.

C. Costs Incurred

The finding that reasonable basis did not support Ms. Frantz’s claim after

March 16, 2016, means that Ms. Frantz is not eligible for reimbursement of

expenses incurred after that date. This limits her claim for costs to $33,169.62.

Like attorneys’ fees, a request for reimbursement of costs must be

reasonable. Perreira, 27 Fed. Cl. at 34. Ms. Frantz has provided adequate

documentation for costs of medical records and other expenses, other than Dr.

Tornatore’s work. Ms. Frantz is awarded these costs ($3,769.62) in full.

The bulk of the costs incurred in the relevant time concern Dr. Tornatore.

Reasonable expert fees are determined using the lodestar method, in which a

reasonable hourly rate is multiplied by a reasonable number of hours. Caves v.

Sec'y of Health & Human Servs., 111 Fed. Cl. 774, 779 (2013).

Dr. Tornatore created an invoice in which he has charged $400 per hour for

working 73.50 hours before March 16, 2016. Thus, the amount Dr. Tornatore

requested for this period is $29,400.00

Dr. Tornatore’s number of hours is reasonable.13 Dr. Tornatore spent many

hours reviewing and summarizing Ms. Frantz’s voluminous medical records.

While much of the 56 pages in his report recounting events in Ms. Frantz’s medical

13

The only question concerns Dr. Tornatore’s charge on July 16, 2016, of 3.5 hours for

reviewing MRI films. In his testimony, Dr. Tornatore stated neurologists can review MRI films

in 15-30 minutes, depending on the level of detail. Tr. 61.

30

history turned out not to be relevant to the outcome of the case, Dr. Tornatore’s

efforts were reasonable.

The problem with Dr. Tornatore’s first report is not the depth of the first 56

pages — the problem is the thinness of the remaining 3 pages. The final three

pages contain Dr. Tornatore’s analysis. Dr. Tornatore relied upon the same set of

articles he cited previously. See, e.g., Day v. Sec’y of Health & Human Servs.,

No. 12-630V, CM/ECF entry 34 (articles filed Jan. 24, 2014). Thus, it is not

entirely clear why Dr. Tornatore spent as much time as he did in reviewing

literature for his first report, although Dr. Tornatore is extended the benefit of the

doubt.

While the number of hours is within the outer bounds of reasonableness, Dr.

Tornatore’s proposed hourly rate ($400 per hour) cannot be accepted. An

appropriate rate for an expert depends, in part, on “the nature, quality, and

complexity of the information provided.” Sabella v. Sec’y of Health & Human

Servs., 86 Fed. Cl. 201, 206 (2009).

Here, Dr. Tornatore’s work—even the work during the time in which

reasonable basis supported the petition—was not commensurate with the work of

an expert charging $400 per hour. As previously discussed, in his first report, Dr.

Tornatore did not identify when Ms. Frantz’s neurologic symptoms began by citing

an exhibit number and page number. This failure to comply with instructions as

well as failure to comply with other instructions necessitated a second report from

Dr. Tornatore, increasing the time that he spent. Then, his second report proposed

an (accurate) onset for her neurologic symptoms but this onset was outside the time

he proposed as consistent with causation in his first report. And perhaps most

importantly, Dr. Tornatore did not consider the significance of the enhanced

lesions on Ms. Frantz’s MRI.

Thus, for this particular case, a reasonable hourly rate for Dr. Tornatore’s

work is $250.00 per hour.14 Cf. Wood v. Sec’y of Health & Human Servs., No.

15-1568V, 2019 WL 518521, at *8 (Fed. Cl. Spec. Mstr. Jan. 11, 2019) (finding

that another expert’s work was so deficient that no compensation was reasonable).

A reasonable amount of compensation for Dr. Tornatore’s work is $18,375.00

14

The undersigned is aware that judges and special masters have sometimes accepted Dr.

Tornatore’s opinions and sometimes rejected his opinions. The undersigned is also aware that

Dr. Tornatore has been compensated at $400 per hour. However, Dr. Tornatore’s awarded

hourly rate in Ms. Frantz’s case depends upon Dr. Tornatore’s work in this case.

31

In sum, Ms. Frantz is awarded attorneys’ costs of $22,144.62.

D. Petitioner’s Costs

Ms. Frantz’s attorneys have adequately documented that they attempted to

communicate with her to obtain her signature on a statement regarding her costs.

They have also represented that Ms. Frantz did not incur any costs. Thus, Ms.

Frantz is not awarded any costs personally.

E. Supplemental Fees

After the oral argument regarding reasonable basis, Ms. Frantz was invited

to submit a motion to request compensation for the time her attorneys spent

litigating fees. See Schuenemeyer v. United States, 776 F.2d 329, 333 (Fed. Cir.

1985). In an April 30, 2019 motion, Ms. Frantz requested an additional $25,537.47

in attorneys’ fees and costs. These fees and costs are reasonable and awarded in

full.

V. Conclusion

After a finding of reasonable basis, the Vaccine Act permits an award of

reasonable attorney’s fees and costs. 42 U.S.C. § 300aa-15(e). For the reasons

explained above, the motion is GRANTED to the extent that the undersigned finds

a reasonable amount to be $135,187.59 (representing $113,042.97 in attorneys’

fees and $22,144.62 in attorneys’ costs). This shall be paid as follows:

A lump sum payment of $135,187.59 in the form of a check made

payable jointly to petitioner and petitioner’s attorney, Ronald Homer,

for all attorneys’ fees and costs available under 42 U.S.C. § 300aa-15(e).

In the absence of a motion for review filed pursuant to RCFC Appendix B,

the clerk of the court is directed to enter judgment herewith.15

IT IS SO ORDERED.

s/Christian J. Moran

Christian J. Moran

Special Master

15

Pursuant to Vaccine Rule 11(a), the parties may expedite entry of judgment by filing a

joint notice renouncing their right to seek review.

32